Ibrutinib followed by ofatumumab consolidation in previously untreated patients with chronic lymphocytic leukemia (CLL): GELLC-7 trial from the Spanish group of CLL (GELLC)

by on 17 de juny de 2024 with No hi ha comentaris
  • Abrisqueta, P., González-Barca, E., Ferrà, C., Ríos-Herranz, E., Fernández de la Mata, M., Delgado, J., Andreu, R., Hernández-Rivas, J. Á., Terol, M. J., Navarro, A., Vidriales, M. B., Baltasar, P., De la Serna, J., Ramírez, Á., Ballester, C., Moreno, C., García-Marco, J. A., Córdoba, R., Yáñez, L., … Bosch, F. (2024). Ibrutinib followed by ofatumumab consolidation in previously untreated patients with chronic lymphocytic leukemia (CLL): GELLC-7 trial from the Spanish group of CLL (GELLC). eClinicalMedicine, 73. https://doi.org/10.1016/j.eclinm.2024.102642

Deixa un comentari

L'adreça electrònica no es publicarà. Els camps necessaris estan marcats amb *